Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 8/20 | 0.48 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823619 | 0.85 | MCL1 (0.62) | PLA2G10SLC9A1MCL1DAOCCR2 | |
| SCHEMBL29475799 | 0.82 | CNR2 (0.44) | PLA2G10SLC9A1MCL1DAOCCR2 | |
| SCHEMBL27580987 | 0.81 | PLA2G10 (0.46) | PLA2G10SLC9A1MCL1DAOCCR2 | |
| SCHEMBL7881984 | 0.81 | ALDH1A1 (0.50) | MCL1DAOF10ALDH1A1TSHR | |
| SCHEMBL30337559 | 0.80 | HTR4 (0.56) | HTR4 | |
| SCHEMBL31257225 | 0.80 | POLB (0.47) | ALDH1A1TSHR | |
| SCHEMBL7884814 | 0.80 | KDM4E (0.46) | MCL1DAOALDH1A1TSHRHTR4 | |
| SCHEMBL28264546 | 0.80 | MCL1 (0.44) | SLC9A1MCL1DAOALDH1A1TSHR | |
| SCHEMBL27695396 | 0.78 | CCR2 (0.41) | PLA2G10SLC9A1MCL1DAOCCR2 | |
| SCHEMBL2323444 | 0.77 | MCL1 (0.71) | PLA2G10SLC9A1MCL1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216961-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CORONAVIRUS INFECTION | Lighthouse Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066776-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CORONAVIRUS INFECTION | Cortexyme, Inc. (US) | 2022-03-31 | — | — | WO | disclosed |